Wall Street analysts forecast that Kura Oncology Inc (NASDAQ:KURA) will post ($0.42) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kura Oncology’s earnings, with the lowest EPS estimate coming in at ($0.46) and the highest estimate coming in at ($0.40). Kura Oncology posted earnings of ($0.37) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 13.5%. The business is scheduled to announce its next earnings report on Monday, March 11th.

According to Zacks, analysts expect that Kura Oncology will report full-year earnings of ($1.72) per share for the current financial year, with EPS estimates ranging from ($1.76) to ($1.70). For the next fiscal year, analysts forecast that the business will report earnings of ($2.01) per share, with EPS estimates ranging from ($2.73) to ($1.80). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Kura Oncology.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, November 5th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.01.

Several research analysts have recently issued reports on KURA shares. ValuEngine upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, November 7th. Cann started coverage on shares of Kura Oncology in a report on Monday, November 5th. They set a “buy” rating and a $35.00 price target for the company. HC Wainwright set a $31.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a report on Thursday, November 1st. Cowen reiterated a “buy” rating on shares of Kura Oncology in a report on Monday, October 22nd. Finally, Zacks Investment Research upgraded shares of Kura Oncology from a “sell” rating to a “buy” rating and set a $18.00 price target for the company in a report on Tuesday, October 16th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $26.86.

KURA traded up $0.52 during trading on Friday, hitting $13.60. 241,538 shares of the stock traded hands, compared to its average volume of 289,108. Kura Oncology has a twelve month low of $10.20 and a twelve month high of $24.02. The company has a market cap of $497.52 million, a P/E ratio of -8.95 and a beta of 4.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.76 and a quick ratio of 14.76.

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 2.1% during the third quarter. Vanguard Group Inc. now owns 1,455,818 shares of the company’s stock worth $25,477,000 after buying an additional 29,785 shares in the last quarter. Teachers Advisors LLC increased its holdings in Kura Oncology by 20.1% in the third quarter. Teachers Advisors LLC now owns 51,013 shares of the company’s stock valued at $893,000 after purchasing an additional 8,536 shares during the period. MetLife Investment Advisors LLC increased its holdings in Kura Oncology by 111.6% in the third quarter. MetLife Investment Advisors LLC now owns 21,375 shares of the company’s stock valued at $374,000 after purchasing an additional 11,273 shares during the period. Point72 Asset Management L.P. increased its holdings in Kura Oncology by 185.1% in the third quarter. Point72 Asset Management L.P. now owns 377,952 shares of the company’s stock valued at $6,614,000 after purchasing an additional 245,406 shares during the period. Finally, Sofinnova Ventures Inc increased its holdings in Kura Oncology by 47.3% in the third quarter. Sofinnova Ventures Inc now owns 247,385 shares of the company’s stock valued at $4,329,000 after purchasing an additional 79,485 shares during the period. Institutional investors own 79.28% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Recommended Story: Fiduciary

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.